Adjuvant T-DXd Cuts Recurrence Risk in Early Breast Cancer

(MedPage Today) — Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast cancer, according to results…